MeSH term
Frequency | Condition_Probility | Animals | 36 | 0.0 |
Humans | 87 | 0.0 |
Research Support, Non-U.S. Gov't | 54 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 25 | 0.0 |
Adenosinetriphosphatase/*metabolism | 6 | 14.0 |
Binding Sites | 3 | 0.0 |
Cell Line | 11 | 0.0 |
DNA Helicases/*metabolism | 8 | 16.0 |
Fluorescent Antibody Technique, Indirect | 4 | 0.0 |
Kinetics | 9 | 0.0 |
Mutagenesis | 2 | 0.0 |
Protein p53/metabolism | 2 | 0.0 |
Adult | 5 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Cell Line, Transformed | 4 | 0.0 |
Cells, Cultured | 10 | 0.0 |
DNA Helicases/*genetics/metabolism | 3 | 21.0 |
Female | 15 | 0.0 |
Fluorescent Antibody Technique | 5 | 0.0 |
DNA Damage | 6 | 0.0 |
*DNA Repair | 5 | 0.0 |
Models, Biological | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 4 | 0.0 |
Blotting, Western | 10 | 0.0 |
DNA Repair | 9 | 1.0 |
Bloom Syndrome/*genetics | 8 | 66.0 |
DNA Helicases/*genetics | 8 | 17.0 |
*Disease Models, Animal | 2 | 0.0 |
English Abstract | 8 | 0.0 |
Mice | 18 | 0.0 |
*Mutation | 2 | 0.0 |
Antibiotics, Antineoplastic/*toxicity | 2 | 15.0 |
Bleomycin/*toxicity | 3 | 25.0 |
Phosphorylation | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Bloom Syndrome/genetics | 4 | 30.0 |
DNA/biosynthesis/*drug effects | 2 | 22.0 |
Flow Cytometry | 4 | 0.0 |
Hydroxyurea/*pharmacology | 2 | 14.0 |
Time Factors | 8 | 0.0 |
Tumor Cells, Cultured | 12 | 0.0 |
*Ultraviolet Rays | 2 | 0.0 |
Alleles | 4 | 0.0 |
Comparative Study | 13 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Molecular Sequence Data | 11 | 0.0 |
Recombination, Genetic/genetics | 2 | 2.0 |
Variation (Genetics) | 2 | 0.0 |
Cell Nucleus/metabolism | 6 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Hela Cells | 11 | 0.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Phenotype | 4 | 0.0 |
Precipitin Tests | 8 | 0.0 |
Protein Binding | 10 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Bloom Syndrome/*enzymology | 3 | 100.0 |
DNA Helicases/genetics/*metabolism | 5 | 22.0 |
Hydroxyurea/pharmacology | 3 | 5.0 |
*Intracellular Signaling Peptides and Proteins | 2 | 0.0 |
*Apoptosis | 4 | 0.0 |
Cell Cycle | 5 | 0.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
In Vitro | 3 | 0.0 |
Microvilli/metabolism | 2 | 6.0 |
DNA Damage/genetics | 2 | 4.0 |
DNA Repair/*genetics | 2 | 0.0 |
Syndrome | 2 | 0.0 |
Adenosinetriphosphatase/metabolism | 2 | 1.0 |
DNA Helicases/metabolism | 2 | 7.0 |
Immunohistochemistry | 3 | 0.0 |
Neoplasm Proteins/*metabolism | 4 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Transfection | 6 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Male | 15 | 0.0 |
Genetic Complementation Test | 3 | 0.0 |
Mutation | 10 | 0.0 |
Recombination, Genetic | 5 | 0.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Methyl Methanesulfonate/pharmacology | 2 | 5.0 |
Micronucleus Tests | 2 | 4.0 |
Adenosinetriphosphatase/chemistry/*metabolism | 2 | 100.0 |
Child | 2 | 0.0 |
DNA Helicases/chemistry/*metabolism | 2 | 28.0 |
DNA Replication | 3 | 0.0 |
K562 Cells | 2 | 0.0 |
Adenosinetriphosphatase/genetics/*metabolism | 2 | 7.0 |
Cell Cycle/*physiology | 2 | 0.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
*DNA Damage | 4 | 0.0 |
DNA Repair/physiology | 2 | 5.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
X-Rays | 2 | 1.0 |
Conserved Sequence | 3 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Models, Genetic | 4 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
*Recombination, Genetic | 2 | 0.0 |
Saccharomyces cerevisiae/metabolism | 2 | 1.0 |
Adenosinetriphosphatase/genetics/metabolism | 3 | 12.0 |
*DNA Replication | 2 | 0.0 |
*Chromosome Aberrations | 2 | 0.0 |
Drug Synergism | 3 | 0.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
Microsatellite Repeats/*genetics | 2 | 0.0 |
Adenosinetriphosphatase/*genetics | 6 | 6.0 |
Amino Acid Sequence | 10 | 0.0 |
Base Sequence | 9 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Exons | 2 | 0.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
DNA Primers | 4 | 0.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Disease Progression | 3 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Mice, Nude | 6 | 0.0 |
Neoplasm Transplantation | 4 | 0.0 |
Transplantation, Heterologous | 2 | 0.0 |
Middle Aged | 3 | 0.0 |
*Nuclear Proteins | 2 | 0.0 |
Signal Transduction | 2 | 0.0 |
DNA Topoisomerases, Type I/*metabolism | 2 | 7.0 |
Rabbits | 3 | 0.0 |
Fibroblasts/cytology/metabolism | 2 | 1.0 |
Enzyme Activation | 3 | 0.0 |
Rats | 6 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Child, Preschool | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Radiation, Ionizing | 2 | 1.0 |
Crosses, Genetic | 2 | 0.0 |
Gene Targeting | 2 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Bleomycin/*pharmacology | 2 | 22.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Fluorouracil/administration & dosage | 2 | 1.0 |
Mitomycin/administration & dosage | 2 | 5.0 |
Epithelium/metabolism | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Bleomycin/*pharmacology/therapeutic use | 2 | 66.0 |
Combined Modality Therapy | 4 | 0.0 |
Antineoplastic Agents/*pharmacology | 5 | 0.0 |
Cell Division/drug effects | 2 | 0.0 |
Cell Survival/drug effects | 3 | 0.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
Bleomycin/pharmacology | 2 | 7.0 |
Lymph Nodes/metabolism | 2 | 3.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Rats, Inbred Strains | 2 | 0.0 |
*Hydroxysteroid Dehydrogenases | 2 | 13.0 |
*Membrane Glycoproteins | 2 | 0.0 |
Genes, p53/genetics | 2 | 0.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Vincristine/administration & dosage | 2 | 1.0 |
DNA/metabolism | 2 | 0.0 |
Sister Chromatid Exchange | 2 | 4.0 |
